Subject: Stem cell therapies

To date, the U.S. FDA has approved 16 cell and gene therapy products, half (8) of which are umbilical cord blood derivatives. 

Approved cord blood derivatives include ALLOCORD, CLEVECORD, HEMACORD, and Ducord, as well as four hematopoietic progenitor cell (HPC) products developed by Clinimmune Labs, MD Anderson Cord Blood Bank, LifeSouth Community Blood Centers, and Bloodworks, respectively. 

As stated by the FDA, "The only stem cell-based products that are FDA-approved for use in the U.S. consist of blood-forming stem cells (hematopoietic progenitor cells) derived from cord blood. These products are approved for limited use in patients with disorders that affect the body system that is involved in the production of blood."

In addition to these FDA approved therapies, a diverse range of stem cell therapies are being offered directly to patients. 

Over the past five years, the number of physicians offering stem cell treatments has expanded exponentially. These services include, but are not limited to, treatments involving stem cells derived from bone marrow, adipose tissue, or peripheral blood, as well as cells derived from umbilical cord blood and tissue, placental blood and tissue, amniotic fluid and tissue, and more. 

Today, there are 425+ medical clinics that provide stem cell services directly to patients. 

With the rapid expansion of this market area, numerous clients requested that we tackle the daunting task of compiling these stem cell treatment providers into a single searchable, sortable database. 

As the world's first and only market research firm to specialize in the stem cell industry, it is not BioInformant's role to assess the regulatory compliance of these medical centers. This responsibility falls squarely under the purview of the U.S. FDA, European EMA, Japanese PMDA, and other regulatory bodies worldwide. 

Rather, our role is to provide a tool for instantly identifying physicians who offer stem cell treatments/therapies within the scope of their medical practice.

Featuring 425+ clinics, the "Database of Stem Cell Treatment Providerswas developed for our own purposes, but we have had more and more clients requesting access to it.

For this reason, we are releasing it to the public – for a limited-time only.

This searchable, sortable Excel database includes:
  1. Name of Medical Center/Clinic
  2. Name(s) of Physicians
  3. Types of Conditions Treated
  4. Types of Stem Cells Administered
  5. Website
  6. City
  7. State
  8. Country
  9. Phone
  10. Email
Created for physicians and industry executives, it can be applied for a wide variety of applications.

For biotech and medical device executives, it can be used to:
  • Identify physicians who would be end-users of your products or services
  • Identify growth of your target market segment
  • Geographically segment your target market
For physicians and medical providers, it can be used to:
  • Assess current levels of market competition 
  • Identity your competitors, including recent market entrants
  • Review the services offered, conditions treated, and stem cell types administered by your competition
It took our team months of intensive research to uncover the identities of these medical centers and compile detailed information about each one. We searched Google for hundreds of relevant keywords, poured over entries within medical directories, and importantly, called and emailed directly with a multitude of physicians. 

The end result is the world’s only searchable, sortable database of stem cell treatment providers that is continuously updated on a daily basis.

To celebrate its December 1st launch, you can claim the database for 50% off (only $97):




Be Great!

The BioInformant Team


p.s. Deciding whether to act? The database has an approval rating of 99.5% and your investment is backed by our Greater than 100% Money Back Guarantee.

Act fast, because this offer expires soon...





BIOINFORMANT | 800 Corporate Drive, Suite 301, Stafford, VA 22554, United States
You may unsubscribe or change your contact details at any time.